<DOC>
	<DOCNO>NCT01536795</DOCNO>
	<brief_summary>This Phase 2 study determine whether WR279396 occlusion ( polyurethane dress ) effective WR279396 without occlusion daily treatment . Extensive objective subjective local tolerance data also capture trial , well surrogate marker ( parasite load aminoglycosides concentration deep dermis ) may help determine optimal number duration treatment . The result study help determine practical treatment schedule answer question crucial improve present treatment regimen WR279396 twice day 20 day .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Tolerance WR279,396 Old World Cutaneous Leishmaniasis</brief_title>
	<detailed_description>Forty-eight patient ( 48 ) Old World cutaneous leishmaniasis randomly allocate WR279396 treatment day 20 day optimize polyurethane dress ( occlusion ) ( 24 patient ) , without occlusion ( 24 patient ) . All patient rescue standard care accept Tunisia , patient cure . The active ingredient WR279396 two aminoglycosides - paromomycin sulphate ( 15 % ) gentamicin sulphate ( 0.5 % ) - base ( AQIC ) . Each subject follow clinical cure 90 day initiation treatment . Cure define 100 % reepithelialization without relapse 3 month . Tolerance evaluate local adverse reaction laboratory sign systemic event . In addition clinical evaluation CL lesion , follow parameters/clinical heal surrogate investigate : 1. parasite load determine superficial deep lesional dermis sample D0 D10 . The mean parasite reduction ratio ( parasite load D10/parasite load D0 ) group compare ; 2. aminoglycoside concentration superficial deep infiltrated dermis group compare .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>The study population select adult ( 18y ) patient child 15y Tunisia ( Old World ) Age : 15 75 year old Lesion character : diameter ( horizontal vertical ) lesion test must measure 7 mm , lesion must primarily ulcerative ( i.e. , verrucous nodular ) locate biopsy friendly site body Parasitological diagnosis : cutaneous leishmaniasis prove parasitologically lesion select inclusion study ( lesion test ) . Informed consent : give write informed consent participate study : ( i.e . patient legal representative ) . Drug intolerance : history know suspected hypersensitivity idiosyncratic reaction aminoglycosides patient immediate family member . Previous use antileishmanial drug ( within 2 month ) present use routinely nephrotoxic ototoxic drug . Potential follow : Have less 4 month time remain present address and/or plan leave area 30 day . Extent disease : More 10 lesion lesion Â³ 5 cm lesion le 2 cm eye , ear , lesion face , opinion attend dermatologist could potentially cause significant disfigurement . Location disease : mucosal involvement . Disseminated disease : clinically significant lymphadenitis nodule painful &gt; 1 cm size lymphatic drainage ulcer . Concomitant medical problem : significant medical problem kidney liver determine history follow laboratory study : Kidney : clinically significant abnormality urine analysis , serum level Creatinine , BUN , total protein &gt; upper limit normal laboratory . Liver : AST ALT &gt; upper limit normal laboratory . General : glucose , Na , K , &gt; upper limit normal &lt; low limit normal laboratory . Volunteers normal laboratory value exceed less 25 % automatically exclude . These volunteer evaluate basis history , physical , well laboratory value . Scheduled ongoing pregnancy determine clinical biological criterion . Presence sign symptoms peripheral neuropathy , myasthenia gravis neuromuscular block</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ointment treat leishmania skin lesion</keyword>
</DOC>